Over 200 companies in the pharmaceutical industry performed well in 3Q
According to CSI, Wind data shows that as of September 25, a total of 574 A-share companies have released their 2020 third-quarter performance forecasts. There are a total of 201 companies with good performance forecasts, some listed companies in the third quarter performance growth rate is obvious, pharmaceutical biology, breeding and technology industry companies perform well.
Specifically, Beixin Building Materials, Shengxiang Biological, Tri-Tai Holdings, Daan Gene, Good Thinking You, StarNet Yuda, Kangtai Medical, Hailian Jinhui, Hongbo shares, *ST Hailu and other companies with the highest year-on-year increase in performance.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
Chemical Weight LossTirzepatide LY3298176 CAS 2023788-19-2 Vial 10mg 20mg Reta Peptide
$114/UNIT FOB
2026-07-20
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Germany Passes Healthcare Reform, Multinational Drugmakers Face 15.5% Mandatory Discount
-
The relationship between Digital Transformation and Work- Life Balance in the Egyptian Pharmaceutical Industry
-
What Does the Future Hold for the Anti-Obesity Drug Market in 2024?
-
CPHI China 2023 | At the Heart of Pharma
-
Hengrui entered the top 20 for the first time. How big is the gap between Chinese and American pharmaceutical companies?
-
The State Food and Drug Administration accepted the marketing application of Ditze Pharma suvortinib
-
Jimin's innovative polycystic kidney disease innovative drug was approved by the FDA for clinical trials
-
Another giant may be broken up
-
NASH is on the verge of a new drug, and the 40-year black hole is finally shining a light
-
Novo Nordisk Shanghai and ShanghaiPharmaceutical Holdings sign a contract to make another breakthrough incooperation
Recommend Reading
-
Wall Street Predicts New Obesity Pills Will Be Priced Near $1000 Like Wegovy and Zepbound Supply and Competition Pressures Mount
-
Glenmark Targets 10–15 Percent CAGR in India by Shifting to High-Margin Drugs AbbVie Deal and New Launches Boost Outlook
-
Novo Nordisk Faces a Compliance Test
-
BioNTech’s Founders Turn the Page
-
India’s API Trade Balance Turns Positive
-
Weak Cost Support for Melamine, This Round of Minor Price Increase May Not Last
-
This Week, the Focus is on Consolidation in China's Titanium Dioxide Market (9.15-9.19)
-
Costs Rise, Demand Increases—January Isooctanol Prices Surge
-
This week, the Aniline market in China saw a slight increase (9.15-9.19)
-
China’s Fixed Asset Investment Hits 28.8 Trillion Yuan in 7 Months Chemical Sector Drops 4.7 Percent as Regional Gaps Widen